Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent.

Ma W, Stroobant V, Heirman C, Sun Z, Thielemans K, Mulder A, van der Bruggen P, Van den Eynde BJ.

J Immunol. 2019 Jan 15;202(2):451-459. doi: 10.4049/jimmunol.1800353. Epub 2018 Dec 17.

PMID:
30559321
2.

Propeptide glycosylation and galectin-3 binding decrease proteolytic activation of human proMMP-9/progelatinase B.

Boon L, Ugarte-Berzal E, Martens E, Vandooren J, Rybakin V, Colau D, Gordon-Alonso M, van der Bruggen P, Stöcker W, Becker-Pauly C, Witters P, Morava E, Jaeken J, Proost P, Opdenakker G.

FEBS J. 2019 Mar;286(5):930-945. doi: 10.1111/febs.14698. Epub 2018 Nov 30.

PMID:
30422384
3.

Extracellular galectins as controllers of cytokines in hematological cancer.

Gordon-Alonso M, Bruger AM, van der Bruggen P.

Blood. 2018 Aug 2;132(5):484-491. doi: 10.1182/blood-2018-04-846014. Epub 2018 Jun 6. Review.

4.

How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions.

Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S.

Cancer Immunol Immunother. 2019 Apr;68(4):631-644. doi: 10.1007/s00262-018-2170-8. Epub 2018 May 21. Review.

PMID:
29785656
5.

Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration.

Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P.

Nat Commun. 2017 Oct 6;8(1):793. doi: 10.1038/s41467-017-00925-6.

6.

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA.

J Clin Oncol. 2017 Oct 10;35(29):3322-3329. doi: 10.1200/JCO.2017.74.5463. Epub 2017 Aug 15.

7.

Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.

Chen X, Wang L, Liu J, Huang L, Yang L, Gao Q, Shi X, Li J, Li F, Zhang Z, Zhao S, Zhang B, Van der Bruggen P, Zhang Y.

Oncol Lett. 2017 Mar;13(3):1609-1618. doi: 10.3892/ol.2017.5665. Epub 2017 Feb 1.

8.

Correlation between the high expression levels of cancer-germline genes with clinical characteristics in esophageal squamous cell carcinoma.

Chen X, Wang L, Yue D, Liu J, Huang L, Yang L, Cao L, Qin G, Li A, Wang D, Wang M, Qi Y, Zhang B, van der Bruggen P, Zhang Y.

Histol Histopathol. 2017 Aug;32(8):793-803. doi: 10.14670/HH-11-847. Epub 2016 Nov 21.

PMID:
27868181
9.

Mesothelioma response to carbon nanotubes is associated with an early and selective accumulation of immunosuppressive monocytic cells.

Huaux F, d'Ursel de Bousies V, Parent MA, Orsi M, Uwambayinema F, Devosse R, Ibouraadaten S, Yakoub Y, Panin N, Palmai-Pallag M, van der Bruggen P, Bailly C, Marega R, Marbaix E, Lison D.

Part Fibre Toxicol. 2016 Aug 23;13(1):46. doi: 10.1186/s12989-016-0158-0.

10.

A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion.

Petit AE, Demotte N, Scheid B, Wildmann C, Bigirimana R, Gordon-Alonso M, Carrasco J, Valitutti S, Godelaine D, van der Bruggen P.

Nat Commun. 2016 Jul 22;7:12242. doi: 10.1038/ncomms12242.

11.

CD8 T-cell responses against the immunodominant Theileria parva peptide Tp249-59 are composed of two distinct populations specific for overlapping 11-mer and 10-mer epitopes.

Connelley TK, Li X, MacHugh N, Colau D, Graham SP, van der Bruggen P, Taracha EL, Gill A, Morrison WI.

Immunology. 2016 Oct;149(2):172-85. doi: 10.1111/imm.12637. Epub 2016 Jul 25.

12.

Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.

Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF.

J Immunother. 2016 Jun;39(5):191-201. doi: 10.1097/CJI.0000000000000123.

13.

Long-Peptide Cross-Presentation by Human Dendritic Cells Occurs in Vacuoles by Peptide Exchange on Nascent MHC Class I Molecules.

Ma W, Zhang Y, Vigneron N, Stroobant V, Thielemans K, van der Bruggen P, Van den Eynde BJ.

J Immunol. 2016 Feb 15;196(4):1711-20. doi: 10.4049/jimmunol.1501574. Epub 2016 Jan 20.

14.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

15.

Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.

Obenaus M, Leitão C, Leisegang M, Chen X, Gavvovidis I, van der Bruggen P, Uckert W, Schendel DJ, Blankenstein T.

Nat Biotechnol. 2015 Apr;33(4):402-7. doi: 10.1038/nbt.3147. Epub 2015 Mar 16.

PMID:
25774714
16.

Sugars boost exhausted tumor-infiltrating lymphocytes by counteracting immunosuppressive activities of galectins.

Gordon-Alonso M, Demotte N, van der Bruggen P.

Oncoimmunology. 2014 Apr 29;3:e28783. eCollection 2014.

17.

Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient.

Abad S, Wieërs G, Colau D, Wildmann C, Delair E, Dhote R, Brézin AP, Kawakami Y, Coulie PG, van der Bruggen P.

Mol Vis. 2014 Jul 2;20:956-69. eCollection 2014.

18.

A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes.

Demotte N, Bigirimana R, Wieërs G, Stroobant V, Squifflet JL, Carrasco J, Thielemans K, Baurain JF, Van Der Smissen P, Courtoy PJ, van der Bruggen P.

Clin Cancer Res. 2014 Apr 1;20(7):1823-33. doi: 10.1158/1078-0432.CCR-13-2459. Epub 2014 Feb 13.

19.

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T.

Nat Rev Cancer. 2014 Feb;14(2):135-46. doi: 10.1038/nrc3670. Review.

PMID:
24457417
20.

Database of T cell-defined human tumor antigens: the 2013 update.

Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P.

Cancer Immun. 2013 Jul 15;13:15. Print 2013. Review.

21.

IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma.

Lorenzi S, Forloni M, Cifaldi L, Antonucci C, Citti A, Boldrini R, Pezzullo M, Castellano A, Russo V, van der Bruggen P, Giacomini P, Locatelli F, Fruci D.

PLoS One. 2012;7(10):e46928. doi: 10.1371/journal.pone.0046928. Epub 2012 Oct 5.

22.

Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells.

Stroobant V, Demotte N, Luiten RM, Leonhardt RM, Cresswell P, Bonehill A, Michaux A, Ma W, Mulder A, Van den Eynde BJ, van der Bruggen P, Vigneron N.

Eur J Immunol. 2012 Jun;42(6):1417-28. doi: 10.1002/eji.201141954.

23.

TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.

Straetemans T, van Brakel M, van Steenbergen S, Broertjes M, Drexhage J, Hegmans J, Lambrecht BN, Lamers C, van Der Bruggen P, Coulie PG, Debets R.

Clin Dev Immunol. 2012;2012:586314. doi: 10.1155/2012/586314. Epub 2012 Feb 12.

24.

Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, van der Bruggen P, Coulie PG, Neyns B, Thielemans K, Bonehill A.

Mol Ther. 2012 May;20(5):1063-74. doi: 10.1038/mt.2012.11. Epub 2012 Feb 28.

25.

Loss of effector function of human cytolytic T lymphocytes is accompanied by major alterations in N- and O-glycosylation.

Antonopoulos A, Demotte N, Stroobant V, Haslam SM, van der Bruggen P, Dell A.

J Biol Chem. 2012 Mar 30;287(14):11240-51. doi: 10.1074/jbc.M111.320820. Epub 2012 Feb 13.

26.

Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.

Wieërs G, Demotte N, Godelaine D, Van der Bruggen P.

Cancers (Basel). 2011 Jul 18;3(3):2904-54. doi: 10.3390/cancers3032904.

27.

A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.

Demotte N, Wieërs G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K, Squifflet JL, Weynand B, Carrasco J, Lurquin C, Courtoy PJ, van der Bruggen P.

Cancer Res. 2010 Oct 1;70(19):7476-88. doi: 10.1158/0008-5472.CAN-10-0761. Epub 2010 Aug 18.

28.

Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens.

Kholmanskikh O, van Baren N, Brasseur F, Ottaviani S, Vanacker J, Arts N, van der Bruggen P, Coulie P, De Plaen E.

Int J Cancer. 2010 Oct 1;127(7):1625-36. doi: 10.1002/ijc.25182.

29.

The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.

François V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, van der Bruggen P.

Cancer Res. 2009 May 15;69(10):4335-45. doi: 10.1158/0008-5472.CAN-08-3726. Epub 2009 May 12.

30.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, François V, Colau D, van der Bruggen P, Neyns B, Thielemans K.

Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.

31.

Comparison of stable human Treg and Th clones by transcriptional profiling.

Stockis J, Fink W, François V, Connerotte T, de Smet C, Knoops L, van der Bruggen P, Boon T, Coulie PG, Lucas S.

Eur J Immunol. 2009 Mar;39(3):869-82. doi: 10.1002/eji.200838807.

32.

[Is it possible to correct the anergy of T lymphocytes that infiltrate tumors?].

van der Bruggen P.

Bull Mem Acad R Med Belg. 2009;164(5-6):183-91; discussion 192. French.

PMID:
20666149
33.

[General principles and first clinical trials of therapeutic vaccines against cancer].

Baurain JF, Van der Bruggen P, Van den Eynde BJ, Coulie PG, Van Baren N.

Bull Cancer. 2008 Mar;95(3):327-35. doi: 10.1684/bdc.2008.0588. Review. French.

34.

Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.

Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet JL, Mourad M, Godelaine D, Boon T, van der Bruggen P.

Immunity. 2008 Mar;28(3):414-24. doi: 10.1016/j.immuni.2008.01.011.

35.

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.

Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D.

J Immunol. 2008 Mar 1;180(5):3585-93.

36.

Characterization of the fine specificity of bovine CD8 T-cell responses to defined antigens from the protozoan parasite Theileria parva.

Graham SP, Pellé R, Yamage M, Mwangi DM, Honda Y, Mwakubambanya RS, de Villiers EP, Abuya E, Awino E, Gachanja J, Mbwika F, Muthiani AM, Muriuki C, Nyanjui JK, Onono FO, Osaso J, Riitho V, Saya RM, Ellis SA, McKeever DJ, MacHugh ND, Gilbert SC, Audonnet JC, Morrison WI, van der Bruggen P, Taracha EL.

Infect Immun. 2008 Feb;76(2):685-94. Epub 2007 Dec 10.

37.

Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity.

Erfurt C, Sun Z, Haendle I, Schuler-Thurner B, Heirman C, Thielemans K, van der Bruggen P, Schuler G, Schultz ES.

J Immunol. 2007 Jun 15;178(12):7703-9.

38.

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde BJ, Knuth A, Boon T.

J Immunol. 2007 Mar 1;178(5):2617-21. No abstract available.

39.

A novel strategy for the identification of antigens that are recognised by bovine MHC class I restricted cytotoxic T cells in a protozoan infection using reverse vaccinology.

Graham SP, Honda Y, Pellé R, Mwangi DM, Glew EJ, de Villiers EP, Shah T, Bishop R, van der Bruggen P, Nene V, Taracha EL.

Immunome Res. 2007 Feb 9;3:2.

40.

Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family.

Wang XF, Cohen WM, Castelli FA, Almunia C, Lethé B, Pouvelle-Moratille S, Munier G, Charron D, Ménez A, Zarour HM, van der Bruggen P, Busson M, Maillère B.

Cancer Immunol Immunother. 2007 Jun;56(6):807-18. Epub 2006 Sep 20.

PMID:
16988823
41.

CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation.

Carrasco J, Godelaine D, Van Pel A, Boon T, van der Bruggen P.

Blood. 2006 Nov 1;108(9):2897-905. Epub 2006 Jul 20.

42.

Human T cell responses against melanoma.

Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P.

Annu Rev Immunol. 2006;24:175-208. Review.

PMID:
16551247
43.

Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes.

Graham SP, Pellé R, Honda Y, Mwangi DM, Tonukari NJ, Yamage M, Glew EJ, de Villiers EP, Shah T, Bishop R, Abuya E, Awino E, Gachanja J, Luyai AE, Mbwika F, Muthiani AM, Ndegwa DM, Njahira M, Nyanjui JK, Onono FO, Osaso J, Saya RM, Wildmann C, Fraser CM, Maudlin I, Gardner MJ, Morzaria SP, Loosmore S, Gilbert SC, Audonnet JC, van der Bruggen P, Nene V, Taracha EL.

Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3286-91. Epub 2006 Feb 21.

44.

Processing and presentation of tumor antigens and vaccination strategies.

van der Bruggen P, Van den Eynde BJ.

Curr Opin Immunol. 2006 Feb;18(1):98-104. Epub 2005 Dec 15. Review.

PMID:
16343880
45.

A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.

Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P.

Cancer Immunol Immunother. 2006 Jun;55(6):644-52. Epub 2005 Sep 27.

PMID:
16187088
46.

A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.

Ottaviani S, Colau D, van der Bruggen P, van der Bruggen P.

Cancer Immunol Immunother. 2006 Jul;55(7):867-72. Epub 2005 Sep 3.

PMID:
16151806
47.

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T.

J Clin Oncol. 2005 Dec 10;23(35):9008-21. Epub 2005 Aug 1.

PMID:
16061912
48.

A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.

Ottaviani S, Zhang Y, Boon T, van der Bruggen P.

Cancer Immunol Immunother. 2005 Dec;54(12):1214-20. Epub 2005 Jul 16.

PMID:
16025263
49.

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M.

Int J Cancer. 2005 Nov 20;117(4):596-604.

50.

A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.

Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.

Eur J Immunol. 2005 Apr;35(4):1066-75.

Supplemental Content

Loading ...
Support Center